These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34657195)

  • 1. Molecular imaging of cellular immunotherapies in experimental and therapeutic settings.
    Shalaby N; Dubois VP; Ronald J
    Cancer Immunol Immunother; 2022 Jun; 71(6):1281-1294. PubMed ID: 34657195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular imaging of innate immunity and immunotherapy.
    Xia W; Singh N; Goel S; Shi S
    Adv Drug Deliv Rev; 2023 Jul; 198():114865. PubMed ID: 37182699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How Non-invasive
    Iafrate M; Fruhwirth GO
    Front Physiol; 2020; 11():154. PubMed ID: 32327996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.
    Zanganeh S; Spitler R; Hutter G; Ho JQ; Pauliah M; Mahmoudi M
    Immunotherapy; 2017 Sep; 9(10):819-835. PubMed ID: 28877626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-Body Imaging to Assess Cell-Based Immunotherapy: Preclinical Studies with an Update on Clinical Translation.
    Sato N; Choyke PL
    Mol Imaging Biol; 2022 Apr; 24(2):235-248. PubMed ID: 34816284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immunotherapies, their safety and toxicity.
    Alatrash G; Jakher H; Stafford PD; Mittendorf EA
    Expert Opin Drug Saf; 2013 Sep; 12(5):631-45. PubMed ID: 23668362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive imaging in cancer immunotherapy: The way to precision medicine.
    Du Y; Qi Y; Jin Z; Tian J
    Cancer Lett; 2019 Dec; 466():13-22. PubMed ID: 31499119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Imaging of Immunotherapy Targets in Cancer.
    Ehlerding EB; England CG; McNeel DG; Cai W
    J Nucl Med; 2016 Oct; 57(10):1487-1492. PubMed ID: 27469363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo tracking of cellular therapeutics using magnetic resonance imaging.
    Long CM; Bulte JW
    Expert Opin Biol Ther; 2009 Mar; 9(3):293-306. PubMed ID: 19216619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tracking cellular and immune therapies in cancer.
    Kurtz DM; Gambhir SS
    Adv Cancer Res; 2014; 124():257-96. PubMed ID: 25287692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients.
    Volpe A; Adusumilli PS; Schöder H; Ponomarev V
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36137649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET/CT Imaging of
    Li W; Wang Y; Rubins D; Bennacef I; Holahan M; Haley H; Purcell M; Gantert L; Hseih S; Judo M; Seghezzi W; Zhang S; van der Veen EL; Lub-de Hooge MN; de Vries EGE; Evelhoch JL; Klimas M; Hostetler ED
    Mol Imaging Biol; 2021 Apr; 23(2):250-259. PubMed ID: 33104972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanotechnology: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(19):1-43. PubMed ID: 23074489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome Prediction and Evaluation by Imaging the Key Elements of Therapeutic Responses to Cancer Immunotherapies Using PET.
    Bu L; Sun Y; Han G; Tu N; Xiao J; Wang Q
    Curr Pharm Des; 2020; 26(6):675-687. PubMed ID: 31465273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target.
    Mayer KE; Mall S; Yusufi N; Gosmann D; Steiger K; Russelli L; Bianchi HO; Audehm S; Wagner R; Bräunlein E; Stelzl A; Bassermann F; Weichert W; Weber W; Schwaiger M; D'Alessandria C; Krackhardt AM
    Theranostics; 2018; 8(21):6070-6087. PubMed ID: 30613283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular imaging to enlighten cancer immunotherapies and underlying involved processes.
    van der Veen EL; Bensch F; Glaudemans AWJM; Lub-de Hooge MN; de Vries EGE
    Cancer Treat Rev; 2018 Nov; 70():232-244. PubMed ID: 30308466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.